Abstract:The development of mechanism-based, multiscale pharmacokinetic–pharmacodynamic (PK-PD) models for chimeric antigen receptor (CAR)-T cells is needed to enable investigation of in vitro and in vivo correlation of CAR-T cell responses and to facilitate preclinical-to-clinical translation. Toward this goal, we first developed a cell-level in vitro PD model that quantitatively characterized CAR-T cell-induced target cell depletion, CAR-T cell expansion and cytokine release. The model accounted for key drug-specific (CAR-affinity, CAR-densities) and system-specific (antigen densities, E:T ratios) variables and was able to characterize comprehensive in vitro datasets from multiple affinity variants of anti-EGFR and anti-HER2 CAR-T cells. Next, a physiologically based PK (PBPK) model was developed to simultaneously characterize the biodistribution of untransduced T-cells, anti-EGFR CAR-T and anti-CD19 CAR-T cells in xenograft -mouse models. The proposed model accounted for the engagement of CAR-T cells with tumor cells at the site of action. Finally, an integrated PBPK-PD relationship was established to simultaneously characterize expansion of CAR-T cells and tumor growth inhibition (TGI) in xenograft mouse model, using datasets from anti-BCMA, anti-HER2, anti-CD19 and anti-EGFR CAR-T cells. Model simulations provided potential mechanistic insights toward the commonly observed multiphasic PK profile (i.e., rapid distribution, expansion, contraction and persistence) of CAR-T cells in the clinic. Model simulations suggested that CAR-T cells may have a steep dose-exposure relationship, and the apparent Cmax upon CAR-T cell expansion in blood may be more sensitive to patient tumor-burden than CAR-T dose levels. Global sensitivity analysis described the effect of other drug-specific parameters toward CAR-T cell expansion and TGI. The proposed modeling framework will be further examined with the clinical PK and PD data, and the learnings can be used to inform design and development of future CAR-T therapies.

Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome

A Computational Model of Cytokine Release Syndrome during CAR T‐Cell Therapy

Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model

Model-Based Cellular Kinetic Analysis Of Chimeric Antigen Receptor-T Cells In Humans

Quantification of CAR T cell performance against acute myeloid leukemia using Bayesian inference

Macrophage, the potential key mediator in CAR-T related CRS

CAR T cells for T-cell leukemias: Insights from mathematical models

CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models

Cytokine Release Syndrome in Cancer Immunotherapy with Chimeric Antigen Receptor Engineered T Cells.

Nonlinear dynamics of CAR-T cell therapy

A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy

Predictive Role of Endothelial Cell Activation in Cytokine Release Syndrome after Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukaemia

A Mathematical Model of TCR-T Cell Therapy for Cervical Cancer

Mathematical model of CAR-T-cell therapy for a B-cell Lymphoma lymph node

Neutrophil Activation and Clonal CAR-T Re-Expansion Underpinning Cytokine Release Syndrome During Ciltacabtagene Autoleucel Therapy in Multiple Myeloma

Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects

Mathematical Modeling Insights into Improving CAR T cell Therapy for Solid Tumors: Antigen Heterogeneity and Bystander Effects

Control-Oriented Models Inform Synthetic Biology Strategies in CAR T Cell Immunotherapy

Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T

In silico assessment of CAR macrophages activity against SARS-CoV-2 infection

Quantitative pharmacology of dual‐targeted bicistronic CAR‐T‐cell therapy using multiscale mechanistic modeling